Nexthera Capital’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Nexthera Capital’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-8,787	Closed	-$3.02M	–	50
2017 Q1	$3.02M	Hold	8,787	–	–	1.54%	17
2016 Q4	$3.07M	Sell	8,787 -13	-0.1%	-$4.76K	1.8%	16
2016 Q3	$3.54M	Buy	8,800 +8,333	+1,784%	+$4.25M	2.17%	15
2016 Q2	$277K	Buy	+467	New	+$284K	0.24%	34

Other funds holding EIGR

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LOAMU

Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return

Nexthera Capital's EIGR Position: Q2 2017 in Review

Nexthera Capital sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2017, closing a stake of 8,787 shares — an estimated $3.02M sold.

Nexthera Capital first reported a position in EIGR in Q2 2016 and held it in 4 quarters. The position peaked at $3.54M in Q3 2016. 39 funds tracked by Wall St. Rank hold EIGR as of Q2 2017.

Nexthera Capital reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
Nexthera Capital sold 8,787 Eiger BioPharmaceuticals, Inc. shares in Q2 2017, an estimated $3.02M.
Nexthera Capital first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2016 and held it in 4 quarters.
Nexthera Capital's Eiger BioPharmaceuticals, Inc. position peaked at $3.54M in Q3 2016.
39 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2017.

Based on Nexthera Capital's 13F filing for Q2 2017, filed 14 Aug 2017.